

Hybrigenics' General Meeting Highlights

Paris, 11 June 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and a fully-owned subsidiary dedicated to protein interaction services reports today the highlights of its general meeting held on June 07, 2012.

The shareholders ratified the nomination of Dr. Alain Munoz and M. Piet Serrure as independent Directors and approved with an overwhelming majority all the other resolutions supported by the Board of Directors, including those related to both the statutory and consolidated financial accounts for 2011.

The license and research collaboration contract with Servier on ubiquitin-specific proteases and the continued growth in both revenue and profitability of Hybrigenics Services' business were mentioned as key events for 2011. Additionally, the shareholders were informed about the recent preliminary results of the Phase II clinical study on oral inecalcitol in moderate to severe psoriasis. The study has been completed in less than a year but the current results did not allow to drawing firm conclusions about efficacy. A study in chronic lymphocytic leukemia is about to start.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.

Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
hybrigenics@newcap.fr